NEW YORK (GenomeWeb News) – Laboratory Corporation of America is planning on expanding its portfolio of genomics-based diagnostics, CEO David King said this week at the JP Morgan Healthcare Conference.

"We never want to get away from the core [testing] business, because the core business is very fundamental to the delivery of healthcare and to patient care," King said in his presentation, which was webcast. "But we want to migrate the business to where we can continue to be seen as a value adder in the value chain."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.